Literature DB >> 18973577

The nigrostriatal dopamine system of aging GFRalpha-1 heterozygous mice: neurochemistry, morphology and behavior.

Vandana Zaman1, Heather A Boger, Ann-Charlotte Granholm, Baerbel Rohrer, Alfred Moore, Mona Buhusi, Greg A Gerhardt, Barry J Hoffer, Lawrence D Middaugh.   

Abstract

Given the established importance of glial cell line-derived neurotrophic factor (GDNF) in maintaining dopaminergic neurotransmitter systems, the nigrostriatal system and associated behaviors of mice with genetic reduction of its high-affinity receptor, GDNF receptor (GFR)alpha-1 (GFRalpha-1(+/-)), were compared with wild-type controls. Motor activity and the stimulatory effects of a dopamine (DA) D1 receptor agonist (SKF 82958) were assessed longitudinally at 8 and 18 months of age. Monoamine concentrations and dopaminergic nerve terminals in the striatum and the number of dopaminergic neurons in the substantia nigra (SN) were assessed. The results support the importance of GFRalpha-1 in maintaining normal function of the nigrostriatal dopaminergic system, with deficits being observed for GFRalpha-1(+/-) mice at both ages. Motor activity was lower and the stimulatory effects of the DA agonist were enhanced for the older GFRalpha-1(+/-) mice. DA in the striatum was reduced in the GFRalpha-1(+/-) mice at both ages, and tyrosine hydroxylase-positive cell numbers in the SN were reduced most substantially in the older GFRalpha-1(+/-) mice. The combined behavioral, pharmacological probe, neurochemical and morphological measures provide evidence of abnormalities in GFRalpha-1(+/-) mice that are indicative of an exacerbated aging-related decline in dopaminergic system function. The noted deficiencies, in turn, suggest that GFRalpha-1 is necessary for GDNF to maintain normal function of the nigrostriatal dopaminergic system. Although the precise mechanism(s) for the aging-related changes in the dopaminergic system remain to be established, the present study clearly establishes that genetic reductions in GFRalpha-1 can contribute to the degenerative changes observed in this system during the aging process.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973577      PMCID: PMC2704551          DOI: 10.1111/j.1460-9568.2008.06456.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  84 in total

1.  Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS.

Authors:  M Trupp; N Belluardo; H Funakoshi; C F Ibáñez
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

2.  Dopaminergic neurons intrinsic to the primate striatum.

Authors:  R Betarbet; R Turner; V Chockkan; M R DeLong; K A Allers; J Walters; A I Levey; J T Greenamyre
Journal:  J Neurosci       Date:  1997-09-01       Impact factor: 6.167

3.  DAD1- and DAD2-like agonist effects on motor activity of C57 mice: differences compared to rats.

Authors:  J P Halberda; L D Middaugh; B E Gard; B P Jackson
Journal:  Synapse       Date:  1997-05       Impact factor: 2.562

4.  Effects of glial cell line-derived neurotrophic factor on the nigrostriatal dopamine system in rodents and nonhuman primates.

Authors:  D M Gash; G A Gerhardt; B J Hoffer
Journal:  Adv Pharmacol       Date:  1998

5.  Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradrenergic denervation.

Authors:  J Harro; L Oreland; E Vasar; J Bradwejn
Journal:  Eur Neuropsychopharmacol       Date:  1995-12       Impact factor: 4.600

6.  The messenger RNAs for both glial cell line-derived neurotrophic factor receptors, c-ret and GDNFRalpha, are induced in the rat brain in response to kainate-induced excitation.

Authors:  M Reeben; A Laurikainen; J O Hiltunen; E Castrén; M Saarma
Journal:  Neuroscience       Date:  1998-03       Impact factor: 3.590

7.  Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-hydroxydopamine lesioned striatum.

Authors:  A C Granholm; J L Mott; K Bowenkamp; S Eken; S Henry; B J Hoffer; P A Lapchak; M R Palmer; C van Horne; G A Gerhardt
Journal:  Exp Brain Res       Date:  1997-08       Impact factor: 1.972

8.  Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.

Authors:  R J Mandel; S K Spratt; R O Snyder; S E Leff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

9.  Cellular and developmental patterns of expression of Ret and glial cell line-derived neurotrophic factor receptor alpha mRNAs.

Authors:  C A Nosrat; A Tomac; B J Hoffer; L Olson
Journal:  Exp Brain Res       Date:  1997-07       Impact factor: 1.972

10.  Localization of glial cell line-derived neurotrophic factor receptor alpha and c-ret mRNA in rat central nervous system.

Authors:  G W Glazner; X Mu; J E Springer
Journal:  J Comp Neurol       Date:  1998-02-02       Impact factor: 3.215

View more
  11 in total

1.  Aged monkeys as a partial model for Parkinson's disease.

Authors:  P J Hurley; J D Elsworth; M C Whittaker; R H Roth; D E Redmond
Journal:  Pharmacol Biochem Behav       Date:  2011-05-18       Impact factor: 3.533

2.  Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF.

Authors:  Ofelia M Littrell; Ann-Charlotte Granholm; Greg A Gerhardt; Heather A Boger
Journal:  Pharmacol Biochem Behav       Date:  2013-01-02       Impact factor: 3.533

3.  Prenatal LPS increases inflammation in the substantia nigra of Gdnf heterozygous mice.

Authors:  Ann-Charlotte Granholm; Vandana Zaman; Jennifer Godbee; Michael Smith; Riad Ramadan; Claudia Umphlet; Patrick Randall; Narayan R Bhat; Baerbel Rohrer; Lawrence D Middaugh; Heather A Boger
Journal:  Brain Pathol       Date:  2010-12-08       Impact factor: 6.508

4.  Biphasic dopamine regulation in mesoaccumbens pathway in response to non-contingent binge and escalating methamphetamine regimens in the Wistar rat.

Authors:  Courtney M Keller; Michael F Salvatore; Brandon S Pruett; Glenn F Guerin; Nicholas E Goeders
Journal:  Psychopharmacology (Berl)       Date:  2011-04-27       Impact factor: 4.530

5.  Modulation of nigral dopamine signaling mitigates parkinsonian signs of aging: evidence from intervention with calorie restriction or inhibition of dopamine uptake.

Authors:  Michael F Salvatore; Ella A Kasanga; D Parker Kelley; Katy E Venable; Tamara R McInnis; Mark A Cantu; Jennifer Terrebonne; Kathryn Lanza; Samantha M Meadows; Ashley Centner; Christopher Bishop; Donald K Ingram
Journal:  Geroscience       Date:  2022-05-30       Impact factor: 7.713

6.  Nigral GFRα1 infusion in aged rats increases locomotor activity, nigral tyrosine hydroxylase, and dopamine content in synchronicity.

Authors:  Brandon S Pruett; Michael F Salvatore
Journal:  Mol Neurobiol       Date:  2013-01-16       Impact factor: 5.590

7.  Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFR alpha1, gene.

Authors:  Heather A Boger; Lawrence D Middaugh; Vandana Zaman; Barry Hoffer; Ann-Charlotte Granholm
Journal:  Brain Res       Date:  2008-09-16       Impact factor: 3.252

8.  Non-invasive brain stimulation: enhancing motor and cognitive functions in healthy old subjects.

Authors:  Maximo Zimerman; Friedhelm C Hummel
Journal:  Front Aging Neurosci       Date:  2010-12-01       Impact factor: 5.750

Review 9.  A dual-hit animal model for age-related parkinsonism.

Authors:  Heather A Boger; Ann-Charlotte Granholm; Jacqueline F McGinty; Lawrence D Middaugh
Journal:  Prog Neurobiol       Date:  2009-10-21       Impact factor: 11.685

10.  Impaired Latent Inhibition in GDNF-Deficient Mice Exposed to Chronic Stress.

Authors:  Mona Buhusi; Colten K Brown; Catalin V Buhusi
Journal:  Front Behav Neurosci       Date:  2017-10-10       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.